Serial Number
88664224
Owner
APTEVO THERAPEUTICS INC.Attorney
Monica Riva TalleyFiling Date
Oct 22, 2019
VYDAPTIV Trademark
Serial Number: 88664224
Trademark Classes
Class 1 - Chemicals
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Owner Contact Info
Legal Representation
Trademark Details
Filing Date
October 22, 2019
Registration Date
Not Registered
Published for Opposition
March 3, 2020
Goods & Services
Pharmaceutical preparations containing polypeptides, antibodies, or antibody derivatives for the treatment and prophylaxis of cancer and immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases
Therapeutic protein molecules used in the manufacture of pharmaceutics and biologically-derived medical preparations; all the foregoing to exclude such molecules relating to antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases
Research and development in the pharmaceutical and biotechnology fields relating to polypeptides, antibodies or antibody derivatives, in relation to the treatment and prophylaxis of cancer, immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude research and development in relation to antibiotics and the treatment and prophylaxis of infectious diseases
